Proefschrift

Hirata, Y., Azuma, S., and Aihara, K. (2014). Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer. Methods , 67(3):278–281. 109 Hirata, Y., Morino, K., Akakura, K., Higano, C., and Aihara, K. (2018a). Personalizing androgen suppression for prostate cancer using mathematical modeling. Scientific Reports , 8(1):1–8. 12, 98 Hirata, Y., Morino, K., Akakura, K., Higano, C., and Aihara, K. (2018b). Personalizing androgen suppression for prostate cancer using mathematical modeling. Scientific reports , 8(1):1–8. 14, 64 Hofbauer, J., Sigmund, K., et al. (1998). Evolutionary games and population dynamics . Cambridge university press. 13, 14, 81 Holohan, C., Schaeybroeck, S., Longley, D., and Johnston, P. (2013). Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer , 13:714–726. 81 Holt, R. and Hochberg, M. (1997). When is biological control evolutionarily stable (or is it)? Ecology , 78(6):1673–1683. 21 Huang, C., Mezencev, R., McDonald, J., and Vannberg, F. (2017). Open source machine- learning algorithms for the prediction of optimal cancer drug therapies. PLoS One , 12(10):e0186906. 109 Huang, S., Lertora, J., Markey, S., and Atkinson Jr, A. (2012). Principles of clinical pharmacology . Academic Press. 87 Huggins, C. and Hodges, C. (1972). Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians , 22(4):232–240. 5 Huss, M., Duhan, P., Gandhi, P., Chen, C., Spannhuth, C., and Kumar, V. (2017). Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatric Disease and Treatment , 13(1):1741–1751. 96 Hussain, M., Goldman, B., Tangen, C., Higano, C., Petrylak, D., Wilding, G., Akdas, A., Small, E., Donnelly, B., Sundram, S., et al. (2009). Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. Journal of Clinical Oncology , 27(15):2450–2456. 112 Hussain, M., Tangen, C., Berry, D., Higano, C., Crawford, D., Liu, G., Wilding, G., Prescott, S., Kanaga Sundaram, S., and Small, E. (2013). Intermittent versus continuous androgen deprivation in prostate cancer. New England Journal of Medicine , 368(14):1314–1325. 49, 50, 52, 58, 104 175